The present studies were performed to investigate whether the differences described between the two modalities for interruption of the renin-angiotensinaldosterone system (RAAS), angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin AT 1receptor antagonists (AIIA) result in differences in renoprotective efficacy in the rat remnant kidney model. Male Sprague-Dawley rats with an initial body weight of 225-300 g, underwent 5/6 renal ablation and had radiotransmitters installed for radiotelemetric blood pressure (BP) measurements, owing to the known limitations of periodic tail-cuff BP measurements to adequately reflect ambient BP profiles. After renal ablation surgery, the rats received no treatment (n=10); enalapril (n=11) or candesartan (n=9) after the first week, both administered initially at a dose of 50 mg/l of drinking water (~10 mg/kg). However, the dose of candesartan had to be reduced to 10-25 mg/l in 4/9 rats to avoid excessive hypotension. Both enalapril and candesartan produced significant reductions in average systolic BP during the subsequent approximately six weeks of observations as compared with untreated rats (187±4 mmHg, p<0.001), but candesartan was significantly more effective at these relative doses (121±3 vs. 133±4 mmHg, p<0.05). At approximately seven weeks, serum creatinine and proteinuria were measured before sacrifice for morphologic assessment of percentage glomerulosclerosis (GS). Despite the described differences between ACE-I and AIIA after acute administration, the percentage GS was reduced similarly by enalapril (down to 6.8±2.8%) and candesartan (down to 2.9±1.5%) as compared with untreated rats (37.2±4.3%). Moreover, GS in individual animals paralleled the BP reductions achieved. Proteinuria was reduced in parallel to the decrease in % GS. These data indicate that, at least in the 5/6 renal ablation model, RAAS blockade by either ACE-I or AIIA provides protection by BPdependent rather than BP-independent mechanisms. This may reflect the primarily hypertensive pathogenesis of GS in this model, and the fact that hypertension is also very angiotensin II-dependent in this model. Thus, these data suggest that models other than the 5/6 ablation model may be more appropriate to demonstrate the BP-independent protective effects of RAAS blockade.
Introduction
The mechanisms responsible for the progressive nature of chronic renal disease continue to be the subject of intense investigation and debate. [1] [2] [3] [4] [5] [6] [7] [8] [9] Data obtained in several experimental models, including the 5/6 renal ablation model, and in human renal disease have shown that blockade of the renin-angiotensin-aldosterone system (RAAS) by either angiotensin-converting enzyme (ACE) inhibition or through angiotensin II (Ang II) receptor (AT 1 ) antagonism is more consistently successful as compared with other blood pressure-(BP)-reducing therapeutic interventions in slowing this progressive glomerulosclerosis (GS) and nephron loss. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] This superior renoprotective ability has generally been attributed to BP-independent protective effects of RAAS blockade. 3, [6] [7] [8] [9] [10] [11] [14] [15] [16] [17] [18] Additionally, it has been suggested that the two modalities of RAAS blockade may not have identical effects. [19] [20] [21] ACE inhibitors (ACE-I), but not AT 1receptor antagonists, are associated with increased bradykinin levels. Bradykinin is postulated to be the mediator of the preferential efferent arteriolar dilation and glomerular capillary pressure (P GC ) reduction observed with ACE-I. 19 Conversely, chronic ACE-I may not eliminate the continued production of Ang II through ACE-independent pathways, albeit at lower but still potentially pathogenic levels. 20 Therefore, it has been suggested that the more distal blockade of RAAS by AT 1 -receptor antagonists may be more effective in blocking the adverse AT 1 -receptor-mediated cellular effects of Ang II as compared with ACE-I. Additionally, it has been suggested that AT 1 -receptor blockade may also result in AT 2 -receptor activation by Ang II, which has the potential for additional beneficial effects. 20, 21 As 'BP effects' are a major variable in such studies, an accurate assessment of ambient BP profiles is a critical requisite for valid conclusions regarding the mechanisms of glomeruloprotection and/or the relative antihypertensive and glomeruloprotective efficacies of therapeutic interventions. BP characteristically exhibits rapid, spontaneous and large fluctuations in conscious unrestrained rats (and most species), particularly when hypertension is present. 12, 13, [22] [23] [24] Such BP lability makes it extremely unlikely that the conventional tail-cuff methodology utilised in such investigations can assess the overall pressure burden with sufficient accuracy to allow definitive conclusions. Therefore, the present studies were undertaken to rigorously examine the relationship of glomeruloprotection to the antihypertensive effects of RAAS blockade in the remnant kidney (RK) model as well as to compare ACE-I with enalapril, vs. AT 1 -receptor antagonism, with candesartan cilexetil, using BP radiotelemetry.
Methods
Studies were conducted in male Sprague-Dawley rats (body weight 225-300 g) fed a standard (24%) protein diet (Purina, St. Louis, MO) and synchronised to a 12:12-hour light (0600-1800 hours) and dark (1800-0600 hours) cycle. All rats received food and water ad libitum throughout the study.
Radiotelemetry
The rats were anaesthetised with sodium pentobarbital (45 mg/kg intraperitoneally), subjected tõ 5/6 renal ablation (right nephrectomy and ligation of all but one posterior extrarenal branch of the left renal artery) and prepared for telemetric monitoring of BP (Data Sciences International, St. Paul, MN) at the time of the renal ablation surgery as previously described. 12, 13, [22] [23] [24] Each rat had a BP sensor inserted intraperitoneally. The radio frequency transmitter was fixed to the peritoneum and the sensor's catheter was inserted into the femoral artery and advanced into the aorta below the level of the renal arteries.The rats were housed individually in plastic cages that were placed on top of the receiver for data acquisition using the Lab Pro data acquisition system (Data Sciences International, St. Paul, MN). Systolic BP in each animal was recorded at 10-minute intervals throughout the course of about seven weeks, with each reading being the average value obtained during a 10 second sampling period (~60 individual BP readings). Tail vein blood samples were obtained at three days for measurement of serum creatinine, as an index of the degree of renal mass reduction. 12, 13, 23, 24 At about seven days, the rats were randomly assigned to the untreated group or received either the ACE-I, enalapril, or the AT 1 -receptor antagonist, candesartan cilexetil, in drinking water at the same dose (50 mg/l,~10 mg/kg/day). In four of nine rats after the initiation of candesartan therapy, the dose had to be reduced to ~12.5-25 mg/l because of excessive hypotension. After the reduction in candesartan dose, the average systolic BP in these rats stayed within the range of other candesartan-treated rats, and no other differences were observed in these rats. After seven weeks, 24-hour urine collections were obtained to measure protein excretion, following which the kidneys were harvested and the rats sacrificed.
Histology
The kidneys were fixed in situ by perfusion for 5 minutes at the measured BP with 1.25% glutaraldehyde in 0.1 M cacodylate buffer. Transverse sections of the kidney through the papilla were cut at a thickness of ~3 µm and stained with haematoxylin and eosin and periodic acid-Schiff. Sections were evaluated systematically in each kidney for glomerular injury (segmental sclerosis and/or necrosis) in a blinded fashion by standard morphologic methods. 12, 13, [22] [23] [24] At least 100 glomeruli in each animal were evaluated, and the severity of GS was expressed as the percentage of glomeruli exhibiting such injury.
Analyses, calculations, and statistics
Urinary protein was measured by the quantitative sulfosalicylic acid method, with human serum albumin serving as standard, and serum creatinine was measured using a creatinine analyser (Beckman Instruments, Inc., Fullerton, CA). 12, 13, [22] [23] [24] Statistical analysis was performed using ANOVA followed by Student-Newman-Keuls test or by Kruskall-Wallis nonparametric ANOVA followed by Dunn's multiple comparison test as appropriate. 25 Results Table 1 shows that the initial body weight, serum creatinine and 24-hour urine protein excretion between the three groups were not significantly different. Similarly, there was no significant difference in serum creatinine at three days between the groups, indicating comparable renal mass reduction in all groups. The final body weight at seven weeks was also not significantly different between the groups. The final serum creatinine was significantly lower in both the treated groups, but the difference in kidney weight was statistically significant only for the candesartan group. Figure 1 (A-C) presents representative illustrations of the systolic BP record of an individual rat from each of the three groups. The course of weekly averages of systolic BP after 5/6 renal ablation for the three groups is shown in Figure 2 (A). The overall averages of systolic BP during the first week after renal ablation (before the initiation of therapy), and during the following six weeks are shown in Figure 2(B) . Although the rats were randomly assigned to the three groups, the rats assigned to the untreated group had a BP which was modestly, but significantly lower by chance during the first week than that of the rats who received the two treatment regimens. Both enalapril and candesartan markedly reduced the average systolic BP, but the BP reduction was more pronounced for the candesartan group. By contrast, the BP in the untreated rats increased significantly over the following six weeks ( Figure 2B ). The protein excretion rate (mg/24 hours) at the end of seven weeks, and the % of glomeruli exhibiting GS in the RKs of these three groups are presented in Figure 3 . Marked reductions in proteinuria and GS were seen in the enalapril-and candesartan-treated groups which paralleled the reductions in BP as compared with the untreated rats. Figure 4 shows the correlation of average systolic BP and GS in all of the individual rats in the study. An excellent direct correlation was observed (slope 0.53±0.53, χ intercept 118.2 mmHg, r=0.89; p<0.0001).
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Discussion
Numerous previous studies have shown that RAAS blockade results in more consistent salutary effects on the progression of both experimental and clinical renal disease as compared with other antihypertensive regimens at comparable levels of BP control. 1, [3] [4] [5] [6] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Although such RAAS blockadeconferred protection is uniformly associated with significant BP reductions, nevertheless the superiority of RAAS blockade has been attributed to 'BPindependent' mechanisms. However, conventional BP measurements are obtained at intervals ranging from one to several weeks, when in fact, BP displays substantial moment-to-moment lability. 22, [26] [27] [28] This fundamental time-dependent BP variability, which persists during treatment with antihypertensive agents including RAAS blockers, 12, 13, 23, 24 renders conventional BP measurements inadequate to examine the relationship between the antihypertensive and renoprotective ability of these agents. The necessity of an accurate assessment of the ambient BP profiles and the pressure burden on the kidneys is demonstrated by the results of our present and previous studies. 12, 13, [22] [23] [24] These studies show that GS exhibits an exceedingly close linear relationship to the overall average systolic BP in both untreated and antihyper- tensive-treated RK rats, indicating that GS in this model is primarily BP-dependent, with differences in the overall BP burden accounting for 65-75% of the variability in GS in individual animals. Thus, it is likely that the inadequacy of the tail-cuff method to accurately assess ambient BP profiles in individual animals and groups in previous studies has resulted in interpretations that magnify the apparent contribution of 'BP-independent' mechanisms to the achieved renoprotection after RAAS blockade in this model. The close correlation observed between systemic BP and GS additionally indicates that P GC profiles parallel the fluctuating systemic pressures in individual animals with 5/6 renal ablation, as GS is expected to be a consequence of an increase in local glomerular pressures, rather than systemic BP per se. Such interpretations are consistent with the demonstrated impairment of the renal autoregulatory mechanisms in rats with 5/6 ablation, which normally provide the primary protection against increases in systemic pressure (episodic or sustained) from being transmitted to the glomerular capillaries. 2, 29 The observation that the dihydropyridine calcium channel blockers cause an additional impairment of renal autoregulation in this model and also have predictable adverse effects on the relationship between BP and GS, provide further support for such an interpretation. 13, 23 These data additionally indicate that isolated one-time measurements of P GC may have the same inherent limitations as isolated, one-time measurements of systemic BP, in addition to being compromised by the effects of anaesthesia-induced activation of the RAAS and neurohormonal systems on segmental vascular resistances.
These results with enalapril and candesartan in the present study are similar to the data previously obtained by us with another ACE-I (benazepril) and another AT 1 -receptor antagonist (losartan). 24 No differences were observed between ACE inhibition and AT 1 -receptor antagonism in either the present or the previous study 24 with respect to the relationship between BP and GS, suggesting that the previously described BP-independent differences between these two methods of RAAS blockade may not play a significant role in the glomeruloprotection during chronic RAAS blockade in the RK model. The predominant importance of BP reduction in the protection provided by individual agents that block the RAAS is also supported by the fact that, despite the differences in the target tissue binding characteristics of candesartan and losartan, 30 neither agent alters the relationship between GS and BP observed in untreated or ACE-I-treated rats (increase in % GS/mmHg increase in average systolic BP). However, such differences between individual AT 1 -receptor antagonists or between AT 1 -receptor antagonists and ACE-I may be relevant to the relative antihypertensive effectiveness of these agents in different models. In the dosages used, greater and more consistent BP reductions were achieved in candesartan-treated rats; however, formal assessments of the doseresponse relationships for the individual agents will be needed to confirm this impression. Such an evaluation is rendered somewhat more difficult in the RK model because of the general effectiveness of all RAAS blockers, probably because the hypertension in this model seems to be largely Ang II-dependent. Therefore, the potential pathogenetic importance of 'BP-independent' pathways associated with RAAS blockade is more likely to be demonstrable in other experimental models where renal damage is less BP-dependent and/or hypertension is less Ang II-dependent than in the 5/6 ablation model. Figure 4 (A) Correlation of the percentage of glomeruli with sclerosis at about seven weeks in individual rats with 5/6 renal ablation and their average systolic BP during the final six weeks (the mean of all 6,000 BP readings in each rat). After the first seven days, the rats had received no treatment, enalapril or candesartan.
Figure 3
Proteinuria (A) and percentage glomerulosclerosis (B) at the end of approximately seven weeks in the rats with 5/6 renal ablation that were left untreated, received enalapril, or candesartan.
